National Fellows Forum
Advertisement
Advertisement
Trending on OncLive
1
Mirvetuximab Soravtansine/Carboplatin Improves ORR But Fails to Extend PFS in FRα-High Recurrent Ovarian Cancer
2
Neoadjuvant Nivolumab Plus Ipilimumab Yields High PFS, OS Rates in Locally Advanced Cervical Cancer
3
Tolerability and ILD Prevention Drive Second-Line Treatment Sequencing in HER2+ NSCLC
4
FDA Accepts sBLA for Subcutaneous Mosunetuzumab Plus Polatuzumab Vedotin in R/R LBCL
5